Follistatin 344
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Follistatin-344 sits in a completely different lane from every other peptide in this wiki. The GH-axis compounds (Ipamorelin, CJC-1295, Sermorelin, Tesamorelin, MK-677 (Ibutamoren)) all work by adding a growth signal — more GH, more IGF-1. Follistatin works the opposite way: by removing an inhibitor. Your body has a built-in brake on muscle growth called myostatin (technically GDF-8, a member of the TGF-β family). Myostatin’s whole job is to keep muscle from growing past a useful set point. Follistatin is your body’s natural inhibitor of myostatin — when follistatin goes up, myostatin gets sequestered, and the brake comes off.
The proof that this pathway works is dramatic and pre-existed any of the synthetic peptides. Belgian Blue cattle carry a natural myostatin mutation and look like cartoon weightlifters. “Bully whippets” (heterozygous myostatin-mutation dogs) are abnormally muscular. A 2004 German case report described a child with a homozygous myostatin loss-of-function mutation who was visibly hyper-muscular as an infant. Myostatin-knockout mice double their lean mass. The pathway is real and the biology is settled — the question is whether you can pharmacologically replicate the knockout phenotype in an adult human without breaking other things.
A naming note worth understanding: follistatin exists in your body as two main circulating isoforms, FS-288 and FS-315. “Follistatin-344” is the precursor form before signal-peptide cleavage that yields FS-315. In commercial / research-peptide contexts, “Follistatin-344” is the synthetic version typically used because of stability and expression characteristics. For practical purposes, this is the synthetic myostatin-neutralizing peptide most users mean when they say “follistatin.”
What does it do in my body?
Follistatin’s mechanism is sequestration. It binds myostatin (GDF-8), activin A, and other TGF-β-family ligands with high affinity, holding them away from their receptors. Myostatin normally signals through the activin receptor type IIB → SMAD2/3 phosphorylation → inhibition of muscle protein synthesis + promotion of muscle atrophy. Take myostatin out of the equation, and you tip the muscle balance toward growth and away from breakdown [ESTABLISHED pharmacology].
Crucial distinction worth holding: follistatin’s action is at the myostatin-muscle axis. It does NOT raise systemic GH or IGF-1. That’s important for two reasons:
- The benefits and risks don’t overlap with the GH-axis catalog — this is its own mechanism class.
- You can in principle stack follistatin with the GH/IGF-1 secretagogues (different pathways, complementary effects on hypertrophy) — though the safety profile of doing so is unstudied.
The activin problem. Follistatin doesn’t only bind myostatin — it also binds activin A, which has system-wide roles (skin integrity, mucosal healing, reproduction, hematopoiesis). Blocking activin too aggressively is what causes the side-effect signature seen with broad TGF-β-family inhibition: nosebleeds, slow wound healing, mucosal issues, reproductive effects, bleeding events. The “holy grail” in this space (and what big pharma is actually chasing with antibody drugs like trevogrumab and garetosmab) is pure myostatin inhibition without activin inhibition. Follistatin doesn’t deliver that — it hits both.
Homeostatic compensation. Tatem makes a point worth carrying forward: human muscle homeostasis is much more redundant than mouse muscle homeostasis. When you crank up follistatin in a human, the body responds by upregulating other inhibitors in the TGF-β family — myostatin elevation itself, GDF-11, others we haven’t catalogued. Mouse hypertrophy doesn’t cleanly translate to human hypertrophy. That’s why the actual human readouts (when they exist) come in much more modest than the rodent picture would predict.
How can it help me?
The myostatin/activin neutralizer. A 344-amino-acid glycoprotein that removes the brake on muscle growth rather than stepping on the accelerator. Different mechanism class from the GH-secretagogue family — doesn’t touch your GH/IGF-1 axis at all. Real biology behind it (Belgian Blue cattle, the “superchild” mutation, knockout mice that look ridiculous), much thinner human evidence base than the marketing suggests, and a unique commercial wrinkle: the most-publicized form is a one-shot gene-therapy plasmid sold offshore for $25K.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The peptide form’s safety surface has a few items worth knowing plainly — none are theoretical.
Documented in clinical / unsupervised-use literature:
- Hepatotoxicity — flagged across multiple secondary sources.
- Endocrine suppression — chronic activin inhibition affects the HPG axis (reproductive hormones).
- Retinal effects — retinal detachment has been documented in clinical trials of injectable myostatin-pathway interventions (the antibody drugs more than follistatin itself, but the class effect applies). This is a class-specific safety surface worth knowing.
- Mucosal / wound-healing effects — downstream of activin blockade; nosebleeds, slow healing.
- Antibody formation — theoretical risk on any multi-week injected peptide; not well-characterized for follistatin specifically.
Mini Circle gene-therapy reported safety: “zero serious AEs” and LDL +8 mg/dL in ~1/3 of patients at 3 months. Vendor-reported, no peer review yet.
Contraindications:
- Active cancer or strong cancer-history risk profile. Myostatin inhibition uncouples a brake on tissue growth — biologically plausible (not proven) concern. Don’t run this with active malignancy.
- Pregnancy, breastfeeding, under-25 developing physiology.
- Active retinal disease given the class signal.
- Active hepatic or renal disease.
Practical management: keep cycles short (8–12 weeks), don’t stack with everything else that promotes growth signaling at once, run baseline + post-cycle labs (LFTs, lipids, ideally a retinal exam if you’re going to do this repeatedly), and treat the foundation — heavy lifting, adequate protein, sleep — as where most of the gain actually comes from.
Regulatory status: Not FDA-approved in either peptide or gene-therapy form. The peptide form sits in the research-chemical gray zone. The plasmid gene-therapy form is delivered exclusively at offshore clinics (Bahamas, Honduras, Panama) — those clinics operate under their own jurisdictions’ frameworks, not US FDA. WADA-banned at all times in sport. Big-pharma activity in the broader myostatin-inhibition space (Regeneron’s trevogrumab, garetosmab antibody drugs targeting myostatin and activin A more selectively) sits separately from the follistatin gray market.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
- Reconstitution math (typical): A 1 mg (1,000 mcg) vial reconstituted with 1 mL bacteriostatic water gives 1,000 mcg/mL. A 150 mcg dose = 0.15 mL = 15 units on a U-100 insulin syringe. (If a 2 mg vial: same logic — 2,000 mcg/mL with 1 mL water; 150 mcg = 7.5 units.)
- Dose: 100–200 mcg per injection.
- Frequency: 2–3× per week.
- Loading-phase variant: Daily injections for week 1, then 2×/week maintenance for the rest of the cycle.
- Cycle: 8–12 weeks on, then a meaningful off period (4–8 weeks) before any rerun.
- Route: Subcutaneous or intramuscular. IM into trained muscle is sometimes used for localized effect, though follistatin’s primary action is systemic.
- Reported gains: “5–10 lb of lean muscle over 8–12 weeks” is the anecdotal vendor framing; the controlled human numbers are far more modest where they exist.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Two delivery paths exist and they’re genuinely different products:
| Path | Peptide injection | Gene-therapy plasmid |
|---|---|---|
| What you inject | Recombinant follistatin protein | A circular DNA plasmid that encodes follistatin |
| Frequency | 2–3× per week, 8–12 weeks per cycle | Single SubQ injection lasting ~1 year |
| Cost model | Recurring per-vial | Lump sum (offshore clinic, ~$25K) |
| Access | Research-peptide market | Bahamas / Honduras / Panama travel-medicine clinics |
| Regulatory | Gray-market research chemical | Not FDA-approved; offshore only |
| Genome integration | N/A (it’s a protein) | No — plasmid stays extra-chromosomal, doesn’t integrate |
| Half-life | Hours-range (the peptide) | Plasmid persists ~1 year inside cells |
For the peptide form (the one a verified-vendor catalog like Alyve could plausibly stock):
For the gene-therapy form: outside Alyve’s lane entirely. Not a research peptide — it’s an experimental gene-therapy procedure delivered at a clinic. OHM can cover it as content (it’s genuinely interesting biotech) but there’s no affiliate path.
What should I avoid combining — and what's synergistic?
Stacking: Different mechanism class from GH/IGF-1, so people do combine follistatin with Ipamorelin / CJC-1295 / Ipamorelin (additive hypertrophy logic across pathways) and with IGF-1 LR3 / MGF (direct downstream growth signal on top of removed brake). The safety profile of those stacks is unstudied — the activin off-target risks compound with anything that pushes growth signaling hard.
How can I buy this?
Follistatin-344 is not in Alyve’s current launch catalog — flagged as a roadmap candidate. The retinal / hepatic / endocrine safety surface, the relatively thin controlled human evidence base, and the dominant offshore-gene-therapy market mean it’s a higher-friction addition than the cleaner muscle/GH-axis SKUs already in the lineup. If Alyve adds it later, the protocol copy will need to lead with the class-specific safety items (retinal, hepatic, activin off-target effects).
What IS in Alyve’s current catalog that addresses the same overall goal (muscle hypertrophy / body composition):
- Ipamorelin, CJC-1295, CJC-1295 / Ipamorelin, Sermorelin, Tesamorelin — the GH/IGF-1 secretagogue lane, with the strongest evidence base of any “muscle peptide” cluster on the market.
- BPC-157, TB-500, Wolverine (BPC-157 + TB-500) — recovery/repair adjuncts that let you train harder and recover better, which is the lift that compounds.
- The cleanest-COA blends: GLOW (BPC + TB + GHK-Cu), KLOW (adds KPV), Wolverine (BPC-157 + TB-500) — all Freedom-Diagnostics verified >99% purity.
The trust angle is the conversion angle: roughly a quarter of the gray-market peptide supply tests fake or underdosed, TFA-salt contamination is invisible to standard HPLC, and follistatin’s online market is one of the most opaque corners of that gray zone. Alyve = US-manufactured, third-party Freedom Diagnostics COAs, >99% verified purity. That’s the floor.
Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly, as always.)
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
The myostatin/activin neutralizer. A 344-amino-acid glycoprotein that removes the brake on muscle growth rather than stepping on the accelerator. Different mechanism class from the GH-secretagogue family — doesn’t touch your GH/IGF-1 axis at all. Real biology behind it (Belgian Blue cattle, the “superchild” mutation, knockout mice that look ridiculous), much thinner human evidence base than the marketing suggests, and a unique commercial wrinkle: the most-publicized form is a one-shot gene-therapy plasmid sold offshore for $25K.
| Class | Glycoprotein myostatin (GDF-8) + activin A neutralizer; TGF-β family inhibitor |
| Mechanism (one-liner) | Binds and sequesters myostatin → removes the brake on muscle protein synthesis → hypertrophy |
| Route | SubQ or IM injection (peptide form); single SubQ plasmid injection (gene-therapy form, offshore) |
| Half-life | Short (hours-range commonly cited) — needs 2–3×/week dosing in peptide form |
| Evidence | Genetic-knockout proof of concept across species; abundant rodent + large-animal hypertrophy studies; Mini Circle 2024 vendor preprint, n≈500; Liz Parrish / BioViva 2015 n=1 self-experiment |
| Regulatory status | Not FDA-approved. Research-chemical classification for the peptide form. Gene-therapy plasmid form delivered only at offshore clinics (Bahamas, Honduras, Panama). WADA-banned. |
| Alyve product | Not in Alyve’s current launch catalog — flagged as a roadmap candidate. (Retinal + hepatic + endocrine safety surface make it a higher-friction addition than the cleaner muscle/GH-axis SKUs.) |
| Primary OHM use case | Honest education on a genuinely novel mechanism (myostatin inhibition) with an editorially-rich gene-therapy parallel — high-traffic content lane, low conversion lane |
What it is
Follistatin-344 sits in a completely different lane from every other peptide in this wiki. The GH-axis compounds (Ipamorelin, CJC-1295, Sermorelin, Tesamorelin, MK-677 (Ibutamoren)) all work by adding a growth signal — more GH, more IGF-1. Follistatin works the opposite way: by removing an inhibitor. Your body has a built-in brake on muscle growth called myostatin (technically GDF-8, a member of the TGF-β family). Myostatin’s whole job is to keep muscle from growing past a useful set point. Follistatin is your body’s natural inhibitor of myostatin — when follistatin goes up, myostatin gets sequestered, and the brake comes off.
The proof that this pathway works is dramatic and pre-existed any of the synthetic peptides. Belgian Blue cattle carry a natural myostatin mutation and look like cartoon weightlifters. “Bully whippets” (heterozygous myostatin-mutation dogs) are abnormally muscular. A 2004 German case report described a child with a homozygous myostatin loss-of-function mutation who was visibly hyper-muscular as an infant. Myostatin-knockout mice double their lean mass. The pathway is real and the biology is settled — the question is whether you can pharmacologically replicate the knockout phenotype in an adult human without breaking other things.
A naming note worth understanding: follistatin exists in your body as two main circulating isoforms, FS-288 and FS-315. “Follistatin-344” is the precursor form before signal-peptide cleavage that yields FS-315. In commercial / research-peptide contexts, “Follistatin-344” is the synthetic version typically used because of stability and expression characteristics. For practical purposes, this is the synthetic myostatin-neutralizing peptide most users mean when they say “follistatin.”
How it works
Follistatin’s mechanism is sequestration. It binds myostatin (GDF-8), activin A, and other TGF-β-family ligands with high affinity, holding them away from their receptors. Myostatin normally signals through the activin receptor type IIB → SMAD2/3 phosphorylation → inhibition of muscle protein synthesis + promotion of muscle atrophy. Take myostatin out of the equation, and you tip the muscle balance toward growth and away from breakdown [ESTABLISHED pharmacology].
Crucial distinction worth holding: follistatin’s action is at the myostatin-muscle axis. It does NOT raise systemic GH or IGF-1. That’s important for two reasons:
- The benefits and risks don’t overlap with the GH-axis catalog — this is its own mechanism class.
- You can in principle stack follistatin with the GH/IGF-1 secretagogues (different pathways, complementary effects on hypertrophy) — though the safety profile of doing so is unstudied.
The activin problem. Follistatin doesn’t only bind myostatin — it also binds activin A, which has system-wide roles (skin integrity, mucosal healing, reproduction, hematopoiesis). Blocking activin too aggressively is what causes the side-effect signature seen with broad TGF-β-family inhibition: nosebleeds, slow wound healing, mucosal issues, reproductive effects, bleeding events. The “holy grail” in this space (and what big pharma is actually chasing with antibody drugs like trevogrumab and garetosmab) is pure myostatin inhibition without activin inhibition. Follistatin doesn’t deliver that — it hits both.
Homeostatic compensation. Tatem makes a point worth carrying forward: human muscle homeostasis is much more redundant than mouse muscle homeostasis. When you crank up follistatin in a human, the body responds by upregulating other inhibitors in the TGF-β family — myostatin elevation itself, GDF-11, others we haven’t catalogued. Mouse hypertrophy doesn’t cleanly translate to human hypertrophy. That’s why the actual human readouts (when they exist) come in much more modest than the rodent picture would predict.
What the research shows
Tiered honestly — and the tiers really matter here because the marketing for this compound runs far ahead of the controlled data.
Genetic-knockout proof of concept. The strongest evidence for the pathway working comes from natural experiments: Belgian Blue cattle (myostatin loss-of-function), bully whippets (heterozygous myostatin mutation), myostatin-null mice (double muscle mass), and the 2004 German “superchild” case. These prove that shutting down myostatin signaling produces dramatic muscle hypertrophy. They do not prove that injecting follistatin in an adult human does the same thing.
Rodent and large-animal studies. Dramatic muscle hypertrophy with follistatin overexpression or myostatin inhibition across multiple species — well-replicated. First-class evidence that the mechanism does what it claims to do, in the species tested.
Mini Circle 2024 preprint — gene-therapy form. Mini Circle is a company running plasmid follistatin gene therapy out of offshore clinics (Roatan, Honduras + similar). Their April 2024 preprint — not peer-reviewed — reports 3-month outcomes across an n of around 500 patients:
- Lean mass: average +2 lb (fat-free mass).
- Body fat: −0.87% body-fat percentage.
- Reported epigenetic age: −12 years in older participants (via TruDiagnostic).
- Zero serious adverse events reported.
- Most common AE: LDL +8 mg/dL in roughly one-third of patients.
- Mini Circle cites a “Jajyan 2021” mouse study for a 32.5% lifespan extension claim.
Treat these numbers with appropriate skepticism: the data is vendor-published, the trial is uncontrolled, and the −12 years epigenetic age claim is extraordinary and needs peer review before it travels. The directionally-positive lean-mass and body-fat numbers are also genuinely modest — +2 lb of fat-free mass over 3 months is comparable to what a beginner lifter gets from training alone.
Brian Johnson’s published Mini Circle data. Derek from More Plates More Dates reported Johnson’s numbers: at 4 months post-injection, circulating follistatin +160%, but at 6 months only +7% lean mass — and Johnson changed many other variables simultaneously. That’s an honest read: the follistatin elevation is real and durable; the lean-mass outcome is small and confounded. Useful as a data point, not as proof of effect.
Liz Parrish / BioViva 2015. Parrish, the BioViva founder, self-administered combined telomerase + follistatin gene therapy. She reported lean-mass gains in the thighs and telomerase elevation persisting 3+ years. Historically important as the first publicly-disclosed human gene-therapy follistatin self-experiment; not clinical-grade evidence.
The injectable peptide path. Direct injectable Follistatin-344 has even thinner human data than the gene-therapy path — most of what’s reported is community-anecdotal. The mechanism is identical, the dosing is more frequent, the half-life is short, and the same caveats about activin off-target effects apply.
Where the science honestly stands: the pathway is real and well-established; the mechanism (myostatin sequestration → reduced atrophy + increased hypertrophy) is biologically sound; the human readouts so far are modest, vendor-reported, and uncontrolled; and the published per-protocol head-to-head against just lifting heavy and eating protein doesn’t exist. As Tatem put it: “The best myostatin inhibitor remains the same as it was in 1975 — heavy squats and enough protein to kill a small horse.” That’s not a dismissal — it’s the foundation any layer of pharmacology gets added on top of.
The size-vs-strength honest caveat. Even when follistatin reliably drives muscle-fiber cross-sectional area (the hypertrophy mechanism), strength gains don’t scale on the same curve. Dr. Ashley Froese frames it bluntly: “It sounds amazing, but in reality, it’s kind of hard to dose. You get really inconsistent results. You got big old muscles, but you can only lift like a chicken.” The mechanism behind this dissociation is plausible — neuromuscular efficiency (motor-unit recruitment, rate coding), tendon-and-connective-tissue load-bearing capacity, and intramuscular coordination all adapt on training-driven timelines (months-to-years), not on the timeline that myostatin-inhibition-driven fiber hypertrophy operates on (weeks). You can grow a muscle bigger than its supporting infrastructure can productively load. Combined with follistatin’s inconsistent-dosing-results reputation in real-world use, this is the most-glossed honest limit in follistatin content. OHM-customer-facing framing: follistatin is a hypertrophy lever, not a strength-and-performance lever — and the size-strength dissociation is real. It pairs better with a properly-loaded training program than it substitutes for one.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. Follistatin-344 is sold for research use only and is not an FDA-approved drug. This is not medical advice. Consult a qualified physician before beginning any protocol.
Two delivery paths exist and they’re genuinely different products:
| Path | Peptide injection | Gene-therapy plasmid |
|---|---|---|
| What you inject | Recombinant follistatin protein | A circular DNA plasmid that encodes follistatin |
| Frequency | 2–3× per week, 8–12 weeks per cycle | Single SubQ injection lasting ~1 year |
| Cost model | Recurring per-vial | Lump sum (offshore clinic, ~$25K) |
| Access | Research-peptide market | Bahamas / Honduras / Panama travel-medicine clinics |
| Regulatory | Gray-market research chemical | Not FDA-approved; offshore only |
| Genome integration | N/A (it’s a protein) | No — plasmid stays extra-chromosomal, doesn’t integrate |
| Half-life | Hours-range (the peptide) | Plasmid persists ~1 year inside cells |
For the peptide form (the one a verified-vendor catalog like Alyve could plausibly stock):
- Reconstitution math (typical): A 1 mg (1,000 mcg) vial reconstituted with 1 mL bacteriostatic water gives 1,000 mcg/mL. A 150 mcg dose = 0.15 mL = 15 units on a U-100 insulin syringe. (If a 2 mg vial: same logic — 2,000 mcg/mL with 1 mL water; 150 mcg = 7.5 units.)
- Dose: 100–200 mcg per injection.
- Frequency: 2–3× per week.
- Loading-phase variant: Daily injections for week 1, then 2×/week maintenance for the rest of the cycle.
- Cycle: 8–12 weeks on, then a meaningful off period (4–8 weeks) before any rerun.
- Route: Subcutaneous or intramuscular. IM into trained muscle is sometimes used for localized effect, though follistatin’s primary action is systemic.
- Reported gains: “5–10 lb of lean muscle over 8–12 weeks” is the anecdotal vendor framing; the controlled human numbers are far more modest where they exist.
Stacking: Different mechanism class from GH/IGF-1, so people do combine follistatin with Ipamorelin / CJC-1295 / Ipamorelin (additive hypertrophy logic across pathways) and with IGF-1 LR3 / MGF (direct downstream growth signal on top of removed brake). The safety profile of those stacks is unstudied — the activin off-target risks compound with anything that pushes growth signaling hard.
For the gene-therapy form: outside Alyve’s lane entirely. Not a research peptide — it’s an experimental gene-therapy procedure delivered at a clinic. OHM can cover it as content (it’s genuinely interesting biotech) but there’s no affiliate path.
Side effects & management
The peptide form’s safety surface has a few items worth knowing plainly — none are theoretical.
Documented in clinical / unsupervised-use literature:
- Hepatotoxicity — flagged across multiple secondary sources.
- Endocrine suppression — chronic activin inhibition affects the HPG axis (reproductive hormones).
- Retinal effects — retinal detachment has been documented in clinical trials of injectable myostatin-pathway interventions (the antibody drugs more than follistatin itself, but the class effect applies). This is a class-specific safety surface worth knowing.
- Mucosal / wound-healing effects — downstream of activin blockade; nosebleeds, slow healing.
- Antibody formation — theoretical risk on any multi-week injected peptide; not well-characterized for follistatin specifically.
Mini Circle gene-therapy reported safety: “zero serious AEs” and LDL +8 mg/dL in ~1/3 of patients at 3 months. Vendor-reported, no peer review yet.
Contraindications:
- Active cancer or strong cancer-history risk profile. Myostatin inhibition uncouples a brake on tissue growth — biologically plausible (not proven) concern. Don’t run this with active malignancy.
- Pregnancy, breastfeeding, under-25 developing physiology.
- Active retinal disease given the class signal.
- Active hepatic or renal disease.
Practical management: keep cycles short (8–12 weeks), don’t stack with everything else that promotes growth signaling at once, run baseline + post-cycle labs (LFTs, lipids, ideally a retinal exam if you’re going to do this repeatedly), and treat the foundation — heavy lifting, adequate protein, sleep — as where most of the gain actually comes from.
Regulatory status
Not FDA-approved in either peptide or gene-therapy form. The peptide form sits in the research-chemical gray zone. The plasmid gene-therapy form is delivered exclusively at offshore clinics (Bahamas, Honduras, Panama) — those clinics operate under their own jurisdictions’ frameworks, not US FDA. WADA-banned at all times in sport. Big-pharma activity in the broader myostatin-inhibition space (Regeneron’s trevogrumab, garetosmab antibody drugs targeting myostatin and activin A more selectively) sits separately from the follistatin gray market.
The Alyve product
Follistatin-344 is not in Alyve’s current launch catalog — flagged as a roadmap candidate. The retinal / hepatic / endocrine safety surface, the relatively thin controlled human evidence base, and the dominant offshore-gene-therapy market mean it’s a higher-friction addition than the cleaner muscle/GH-axis SKUs already in the lineup. If Alyve adds it later, the protocol copy will need to lead with the class-specific safety items (retinal, hepatic, activin off-target effects).
What IS in Alyve’s current catalog that addresses the same overall goal (muscle hypertrophy / body composition):
- Ipamorelin, CJC-1295, CJC-1295 / Ipamorelin, Sermorelin, Tesamorelin — the GH/IGF-1 secretagogue lane, with the strongest evidence base of any “muscle peptide” cluster on the market.
- BPC-157, TB-500, Wolverine (BPC-157 + TB-500) — recovery/repair adjuncts that let you train harder and recover better, which is the lift that compounds.
- The cleanest-COA blends: GLOW (BPC + TB + GHK-Cu), KLOW (adds KPV), Wolverine (BPC-157 + TB-500) — all Freedom-Diagnostics verified >99% purity.
The trust angle is the conversion angle: roughly a quarter of the gray-market peptide supply tests fake or underdosed, TFA-salt contamination is invisible to standard HPLC, and follistatin’s online market is one of the most opaque corners of that gray zone. Alyve = US-manufactured, third-party Freedom Diagnostics COAs, >99% verified purity. That’s the floor.
Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly, as always.)
Sources
- Research note — Follistatin-344 + MK-677 muscle cluster (text aggregation, mechanism + Mini Circle preprint + Parrish + safety items).
- Tatem A. “Doctor PREDICTS Future Muscle Drugs: Bimagrumab, Follistatin, Orforglipron & More” (muscle-drugs landscape; Mini Circle critique; “1975 squats” quote).
- Mini Circle 2024 follistatin gene-therapy preprint. https://minicircle.io/wp-content/uploads/2024/04/fstpreprint.pdf
- Sarah Constantin substack — independent analysis of Mini Circle’s follistatin data. https://sarahconstantin.substack.com/p/minicircle-follistatin-gene-therapy
- Fight Aging — BioViva / Parrish follistatin gene therapy data. https://www.fightaging.org/archives/2016/11/data-on-the-effects-of-follistatin-gene-therapy-from-bioviva/
- peptidedossier.com — Follistatin-344 reference. https://peptidedossier.com/peptides/follistatin-344/
- Schuelke M et al. Myostatin mutation associated with gross muscle hypertrophy in a child (the “superchild” case). N Engl J Med. 2004.
- Belgian Blue / whippet myostatin-mutation natural-experiment literature.
- Alyve COA summary (no follistatin SKU — not in launch catalog).
See also: MK-677 (Ibutamoren), Ipamorelin, CJC-1295, CJC-1295 / Ipamorelin, IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster, GHRP-2, GHRP-6, and Hexarelin — the injectable ghrelin-receptor GH peptides.